Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLS-010 Plus Chemotherapy With or Without Bevacizumab in Cervical Cancer
NCT05798819Phase 3Recruiting
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cervical Cancer (CC) comparing GLS-010+chemotherapy± bevacizumab with Placebo+chemotherapy± bevacizumab (2 arms). Primary endpoint: Overall Survival at 2 years. Started Apr 2023; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05798819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05798819.